• Explore /
  • Poster
  • / FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.

FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.

Abstract Video & Slides Poster

Authors

null

Chiara Cremolini

Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

Chiara Cremolini , Carlotta Antoniotti , Alexander Stein , Johanna C. Bendell , Thomas Gruenberger , Gianluca Masi , Elena Ongaro , Herbert Hurwitz , Alfredo Falcone , Hans-Joachim Schmoll , Massimo Di Maio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4015)

DOI

10.1200/JCO.2020.38.15_suppl.4015

Abstract #

4015

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Kentaro Yamazaki

First Author: Daniele Rossini

First Author: Chiara Cremolini

First Author: Marco Maria Germani